2026-07-21T16:29:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/159822025-05-08T10:44:07Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16978

00925njm 22002777a 4500 dc Gil-Manso, Sergio author Carbonell, Diego author Pérez-Fernández, Verónica Astrid author López-Esteban, Rocío author Alonso, Roberto author Muñoz, Patricia author Ochando, Jordi author Sanchez-Arcilla, Ignacio author Bellón, José María author Correa-Rocha, Rafael author Pion, Marjorie author 2022-07-12 Vaccination against SARS-CoV-2 has become the main method of reducing mortality and severity of COVID-19. This work aims to study the evolution of the cellular and humoral responses conferred by two mRNA vaccines after two doses against SARS-CoV-2. On days 30 and 240 after the second dose of both vaccines, the anti-S antibodies in plasma were evaluated from 82 volunteers vaccinated with BNT162b2 and 68 vaccinated with mRNA-1273. Peripheral blood was stimulated with peptides encompassing the entire SARS-CoV-2 Spike sequence. IgG Anti-S antibodies (humoral) were quantified on plasma, and inflammatory cytokines (cellular) were measured after stimulation. We observed a higher response (both humoral and cellular) with the mRNA-1273 vaccine. Stratifying by age and gender, differences between vaccines were observed, especially in women under 48 and men over 48 years old. Therefore, this work could help to set up a vaccination strategy that could be applied to confer maximum immunity. Biomedicines. 2022 Jul 12;10(7):1676. 10.3390/biomedicines10071676 2227-9059 Biomedicines 35884980 http://hdl.handle.net/20.500.12105/15982 COVID-19 SARS-CoV-2 Cellular responses Humoral responses mRNA-vaccines Cellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccines